Akshintala Venkata S, Boparai Ibadat S, Barakat Monique T, Husain Sohail Z
Division of Gastroenterology, Department of Internal Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
Division of Gastroenterology, Department of Pediatrics, School of Medicine, Stanford University, Stanford, California, USA.
United European Gastroenterol J. 2025 Feb;13(1):78-85. doi: 10.1002/ueg2.12732. Epub 2024 Dec 23.
Endoscopic retrograde cholangiopancreatography (ERCP) is becoming more common than first-line therapy for pancreaticobiliary duct disorders. However, post-ERCP pancreatitis is the most common complication of ERCPs, and affects about 10% of cases. In this review, we provide an overview of the mechanisms purported to cause post-ERCP pancreatitis as well as associated risk factors. We discuss measures that are in practice for post-ERCP pancreatitis pharmaco-prophylaxis, along with advances in the pipeline. We emphasize that there is still a pressing need to narrow the incidence of post-ERCP pancreatitis and that a mechanistic approach may reveal the greatest benefit from utilizing a combination of targets.
内镜逆行胰胆管造影术(ERCP)在治疗胰胆管疾病方面正变得比一线治疗更为常见。然而,ERCP术后胰腺炎是ERCP最常见的并发症,约10%的病例会受到影响。在本综述中,我们概述了据称导致ERCP术后胰腺炎的机制以及相关危险因素。我们讨论了目前用于ERCP术后胰腺炎药物预防的措施以及正在研发的进展。我们强调,仍迫切需要降低ERCP术后胰腺炎的发生率,并且一种基于机制的方法可能会揭示联合使用多种靶点能带来最大益处。